---
layout: default
title: Nitrogen
parent: Model Prediction Only (L5)
nav_order: 342
evidence_level: L5
indication_count: 10
---

# Nitrogen
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nitrogen: From Unspecified Original Indication to 16q24.1 Microdeletion Syndrome

## One-Sentence Summary

Nitrogen (DrugBank DB09152) is registered in South Africa mainly within total parenteral nutrition (TPN) products, and no original indication is recorded in the registration data.
The TxGNN model predicts it may be effective for **16q24.1 microdeletion syndrome**, but there are **0 clinical trials** and **0 publications** for this prediction.
The high score is most likely a modelling artefact, not a biological signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the SAHPRA registration records |
| Predicted New Indication | 16q24.1 microdeletion syndrome |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 12 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Nitrogen is an inert atmospheric or medical gas with no documented pharmacological target. No genetic or pathway rationale connects it to a chromosomal deletion syndrome.

16q24.1 microdeletion syndrome is a developmental disorder caused by loss of chromosomal material. It is not something a small inert molecule would be expected to treat. The score of 99.73% (model rank 1,813) most likely reflects sparse drug data in the knowledge graph rather than real biology. **This prediction is not mechanistically supported and should be treated as a model artefact until proven otherwise.**

## Clinical Trial Evidence

Currently no related clinical trials registered for this predicted indication (ClinicalTrials.gov, ICTRP, SANCTR and PACTR were not found to contain matching studies in the Evidence Pack).

## Literature Evidence

Currently no related literature available for this predicted indication.

## Other Predictions Screened (Context Only)

| Rank | Predicted Indication | Score | Trials | Papers | Assessment |
|------|------|------|------|------|------|
| 2 | Primary interstitial lung disease specific to childhood | 99.72% | 1 | 0 | The only trial ([NCT03869515](https://clinicaltrials.gov/study/NCT03869515)) is an observational genetics study of childhood ILD in China (n=271). It does not test nitrogen. |
| 3 | Isolated pulmonary capillaritis | 99.72% | 0 | 0 | Prediction only |
| 4 | Congenital pulmonary lymphangiectasia | 99.68% | 0 | 0 | Prediction only |
| 5 | Benign neoplasm of adrenal gland | 98.79% | 0 | 20 | The papers are keyword matches on "nitrogen" or "nitric oxide" (a different molecule), not studies of nitrogen as a therapy. |
| 6 | Malformation syndrome with odontal and/or periodontal component | 98.77% | 0 | 20 | The papers cover general periodontitis management and do not involve nitrogen. |
| 7–9 | Dandy-Walker malformation syndrome; isolated genetic hair shaft abnormality; Ambras type hypertrichosis | 98.58–98.67% | 0 | 0 | Prediction only |
| 10 | Hypertrichosis | 98.55% | 0 | 2 | The papers concern cyclosporin A in lupus and De Lange syndrome, not nitrogen. |

All ten predictions are at evidence level L5 with a Hold recommendation.

## South Africa Market Information

| Registration Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| Exclusion under Section 36 & Section 14 | ITN paediatric tpn 107 | Tpn | Not stated |
| Exclusion under Section 36 & Section 14 | ITN 3014Xa 750ml | Tpn | Not stated |
| Article 21B, N/A | TPN non-specific | Infusion | Not stated |
| Exclusion under Section 36 & Section 14 | ITN 8807a 2390ml | Tpn | Not stated |
| Exclusion under Section 36 & Section 14 | ITN 5501a 2240ml | Tpn | Not stated |

Of the 12 records, 5 are shown above. They are TPN preparations listed under exclusion or Article 21B pathways, not standard product registrations with approved indication text. They do not point to any approved therapeutic use of nitrogen itself.

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

No drug-interaction records were found for this compound.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no trials, no literature, no plausible mechanism and no stated original indication. The registrations found are TPN products and do not support the predicted use. Progression is also blocked because SAHPRA package insert safety information is missing.

**To proceed, the following is needed:**
- SAHPRA package insert warnings and contraindications (blocking gap), obtained by downloading and parsing the PI from the SAHPRA website
- Mechanism of action data, e.g. from a DrugBank API query
- A documented biological rationale linking nitrogen to 16q24.1 microdeletion syndrome
- Confirmation that the 12 TPN-related records correspond to the compound evaluated here, as opposed to nitrogen as a formulation component
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

